Prednisolone Addition for Patients With Recent-onset Psychotic Disorder

Phase 4

Terminated

• Conditions: Psychotic Disorder NOS; Schizophrenia; Schizoaffective Disorder; Schizophreniform Disorder
• Interventions: Drug: Placebo Oral Tablet; Drug: Prednisolone

• Registration Number: NCT02949232
• Lead Sponsor: UMC Utrecht

Brief Summary

Treatment with prednisolone can be used as a proof of concept to investigate the possibility of immune modulation as a treatment for schizophrenia. It is expected that daily treatment with prednisolone in addition to antipsychotic treatment reduces psychotic symptoms and improves cognition, as compared to placebo. The investigators propose to investigate the effects of administering the corticosteroid prednisolone versus placebo in addition to standard antipsychotic medication in patients with early stage schizophrenia or related disorders, hypothesizing that a decrease in the overall low-grade cerebral inflammation due to prednisolon treatment will be expressed as a decrease in overall symptom severity., Secondly, addition of prednisolone is hypothesised to slow down cognitive deterioration in recent-onset psychosis patients. Finally, the investigators aim to determine whether indirect immunological parameters of the hypothesised low grade inflammation status in schizophrenia are shifted due to the addition of prednisolone.

Detailed Description

In the current study, the investigators aim to investigate the effect of additional treatment with prednisolone on symptomatic improvement, global functioning, cognition and on immunological parameters in patients with early-stage psychotic disorder, applying a randomized double-blind placebo-controlled add-on design. A placebo-controlled design was chosen in order to differentiate between clinical effects of prednisolone and effects associated with experimental treatment, such as induced expectations of participants. Prednisolone or placebo is provided next to existent antipsychotic medication as the investigators do not intend to replace existing treatment, this study being a Proof of Concept trial. It would carry considerable risks for patients to taper down existent antipsychotic medication and randomize patients to either placebo or a type of therapy for which the efficacy still has to be proven, even for a short period of time.

90 patients with schizophrenia, schizoaffective or schizophreniform disorder, or psychotic disorder NOS (not otherwise specified) will be included, with an age of 18-70 years and a time interval between the onset of psychosis and study entry not exceeding seven years. All 90 in- and outpatients will be randomized 1:1 to either prednisolone or placebo daily for 6 weeks. Prednisolone will be initiated at 40mg/day for 3 days and the 4 remaining days of the first week 30mg/dag will be used. During the treatment period, patients will be seen at weekly intervals to assess symptom severity, depressive mood and suicidal ideation, global functioning and side effects.

Study Timeline

• Study Start: 2014-07
• Study First Submitted: 2016-10-27
• Study First Submitted QC: 2016-10-27
• Study First Posted: 2016-10-31
• Primary Completion: 2019-05
• Study Completion: 2019-05
• Status Verified: 2019-06
• Last Update Submitted: 2019-06-21
• Last Update Posted: 2019-06-24

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 42

Inclusion Criteria

1. A DSM-IV-R diagnosis of: 295.x (schizophrenia, schizophreniform disorder, or schizoaffective disorder) or 298.9 (psychosis NOS)
2. Onset of psychosis no longer than 7 years ago
3. Minimum total PANSS score of 60
4. Age 18 -70 years
5. Patients are treated with antipsychotic medication
6. Written informed consent is obtained
7. Female patients of childbearing potential need to utilize a proper method of contraception (the pill, vaginal ring, hormonal patch, intrauterine device, cervical cap, condom, contraceptive injection, diaphragm) in case of sexual intercourse during the study.

Exclusion Criteria

1. Presence of any of the contra-indications of prednisolone as reported in the SPC.

2. Presence of diabetes mellitus or random (non-fasting) glucose levels exceeding 11 mmol/L at screening, severe heart failure, severe osteoporosis or systemic fungal infections.

3. Body Mass Index (BMI) of >30.0

4. Current or chronic use of systemic glucocorticosteroids (temporary use is permitted, if stopped 1 month before start of treatment trial)

5. Chronic use of non-steroidal anti-inflammatory drugs, defined as daily use during more than 2 months. Intermittent use is permitted, if stopped at least 1 month before start of treatment trial.

6. Pregnancy or breast-feeding. A urine pregnancy test will be performed at screening.

7. Concurrent use of certain types of medication:

8. liver enzyme inducing medication such as carbamazepine, riphampicine, primidone, barbiturates and phenytoine

9. HAART medication (both HIV protease inhibitors and (non)-nucleoside reverse transcriptase inhibitors), especially efavirenz, ritonavir and lopinavir.

10. telaprevir and boceprevir in treatment of Hepatitis C

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo Oral Tablet	Placebo Oral Tablet	Placebo will be initiated at 40 mg for three days, after which it will be phased out within 6 weeks after start, following the treatment schedule of the experimental arm
Prednisolone	Prednisolone	Prednisolone will be initiated at 40 mg for three days, after which it will be phased out within 6 weeks after start, following treatment guidelines for Inflammatory Bowel Diseases (2008).

Primary Outcome Measures

Name	Time	Method
Change in symptom severity	6 weeks	Change in symptom severity is expressed as a change in total score on the Positive and Negative Symptom Scale (PANSS) from baseline to end of the 6-week treatment.

Secondary Outcome Measures

Name	Time	Method
Improvement in cognitive functioning	6 months	Cognitive functioning is measured through the Brief Assessment of Cognition in Schizophrenia (BACS).
Change in GAF scores	1 year	Global Assessment of Functioning
Measurement of various immunological biomarkers	6 months	Cytokine panels will be analysed
Improvement of PANSS scores in follow-up	1 year	PANSS follow-up; 4 months, 6 months and 12 months
Score on the Calgary Depression Scale for Schizophrenia (CDSS)	6 weeks	CDSS scores will be analysed
Incidences of key SAEs and SUSARs	1 year	Safety analyses

Trial Locations

Locations (4)

UMC Utrecht; 🇳🇱 Utrecht, Netherlands

University Aarhus; 🇩🇰 Risskov, Denmark

ZNA; 🇧🇪 Antwerp, Belgium

Yulius; 🇳🇱 Sliedrecht, Netherlands